A study of 18F-FLT positron emission tomography/computed tomography imaging in cases of prefibrotic/early primary myelofibrosis and essential thrombocythemia.
Mohamad A YassinSadek A NehmehAbdulqadir Jeprel NashwanSamah A KohlaShehab F MohamedOmar M IsmailAhmad Al SabbaghFiryal IbrahimDina S SolimanLajos SzabadosHadi FayadPublished in: Medicine (2020)
The objectives of this research project are to study in patients with primary myelofibrosis (PMF) and Essential Thrombocythemia (ET); (1) the uptake patterns of FLT-PET (FLT-PET) and its value in diagnosing, staging, and treatment response monitoring of malignant hematopoiesis, (2) compare imaging findings from FLT-PET with bone marrow biopsy (standard of care), and (3) associate FLT-PET uptake patterns with genetic makeup such as JAK2 (Janus kinase 2), CALR (Calreticulin), MPL (myeloproliferative leukemia protein), Triple negative disease, and allele burden.This trial is registered in ClinicalTrials.gov with number NCT03116542. Protocol version: Mar 2017.
Keyphrases
- positron emission tomography
- acute myeloid leukemia
- computed tomography
- tyrosine kinase
- pet ct
- bone marrow
- pet imaging
- high resolution
- quality improvement
- magnetic resonance imaging
- healthcare
- clinical trial
- image quality
- palliative care
- contrast enhanced
- study protocol
- lymph node
- dual energy
- gene expression
- risk factors
- phase iii
- genome wide
- mass spectrometry
- psychometric properties
- ultrasound guided
- small molecule
- copy number
- phase ii
- photodynamic therapy
- open label
- amino acid